Dear Profit-Seeking Investor:
——There’s a lot at stake here so let me start with the news that could create a fortune in profits for you very shortly.
——I anticipate you could see a quick 2- to 3-fold leap off today’s EFSF share prices following news that eFoodSafety has received EPA approval for its non-toxic Big Six Plus germicidal.
——This has been the key news the company has been waiting for…news that will finally open the doors to a global market for an environmentally safe, non-toxic answer to the bird flu crisis.
——The profit potential for investors is simply enormous.
——My first upside target of $2 puts EFSF in 670% gain potential.
——My second target could be so explosive, it might easily blow past a ten-bagger! I'll be publishing my forecasts and sell signals in The KonLin Letter.
——What’s driving this forecast is that eFoodSafety now has its non-toxic anti-viral formula ready for global distribution.
——Now that it’s received EPA approval, eFoodSafety Big Six Plus germicidal could quickly be disseminated worldwide,
used to combat one of the most urgent health crises in human history, bird flu.
——Let me begin with a quick review of the toll that bird flu has taken thus far. Since its outbreak…
- 151 million domestic birds have died or been killed,
- $10 billion has been lost in agricultural economies, and sadly,
- 63 people have died even before the viral mutation that World Health Organization officials are saying would trigger a global pandemic of Biblical proportions.
——As horrendous as these data are, here is the figure that staggers the imagination.
——At present, about 50% of human patients who contract avian flu could die from the disease, creating a lethal risk of 180-300 million human deaths according to one highly regarded researcher.
——It’s that serious. Ira Longini, from Emory University’s Department of Biostatistics demonstrated the need for an effective, non-toxic weapon to stop the spread of disease using data obtained from an epidemic simulation over 5,625 square kilometers of rural Thailand.
——Longini reports, "You have two to three weeks, if it starts in a rural area, to contain the disease." Longini goes on to say, “With
a reasonably small stockpile of antiviral prophylaxis, you can contain it with a high probability.”
——Please note the phrase: “antiviral prophylaxis.”
——Prophylaxis means applying the remedy before the cure.
Longini’s assessment brings home the importance of a response like what may be possible with the non-toxic eFoodSafety Big Six Plus formula.
This is exactly the use for which Big Six Plus germicidal is intended.
——I can imagine the stampede of countries seeking supplies of Big Six
Plus to clean up bird flu breakouts or stop them from occuring in the first place.
——Is that going to happen? It’s not guaranteed, but I for one do not want to be on the sidelines should this stampede get started. I own this stock myself and have made it my #1 stock pick for 2006. My subscribers are also ready and you could be too.
——Just look at how much America will spend…with no outbreak yet on our soil!
$3.8 billion has been approved for
combating bird flu in America!
——In
November last year, President Bush proposed a whopping $7.1 billion budget to prevent the spread of bird flu to America. By Christmas, Congress had approved $3.8 billion of that request.
——Worldwide, you can anticipate that billions more will be spent attempting to stop bird flu from spreading further.
——When that kind of money is thrown at a problem of this magnitude, fortunes will be made, of that you can be certain.
What’s more, further tests suggest that a similar eFoodSafety formula can be used as an oral treatment for influenza patients!
Human trials are already underway!
——Clinical trials at one of America’s top pharmaceutical testing laboratories, Bucks County Clinical Research, are being conducted to show that eFoodSafety’s Citroxin O2 germicidal formula can kill influenza A & B virus in vivo. (Since no patients can be tested with bird flu, the efficacy against bird flu virus will be inferred.)
——This is the same research lab that routinely tests for major pharmaceutical companies like Roche, Bristol Myers and others.
There’s even evidence that the germicidal formula could lead to an
effective therapy for the common cold! Wouldn’t that be nice...and profitable!
——In agricultural applications, Big Six Plus can be sprayed almost anywhere that bird flu is found…in chicken coops, poultry feed, nesting areas, food processing areas, etc. It's even being considered as an additive to poultry feed for prevention or treatment of disease.
——So why is eFoodSafety’s product not being sprayed from airplanes right now? Good question. Now that the EPA has signed it off as non-toxic, it may well come to that!
——After all...something must be used to stop bird
flu…and this could be it!
Big Six Plus is proven effective…proven safe…and ready for global sales!
It’s non-toxic to humans and animals, can be used almost anywhere.
And it’s devastating to a long list of pathogens such as these nasty bugs:
It eradicates black mold…the destroyer of homes!——eFoodSafety has been selling the Citroxin cleaner for its proven, 100% effectiveness at wiping out the black mold (stachybotrys chartarum) overrunning hurricane-ravaged areas of the South. Unlike the
toxic, marginally effective alternatives, Citroxin can be sprayed cost-effectively without immediate or lasting impact on humans, animals or the environment. I expect significant sales from this product in the coming year.
It sanitizes food, prep surfaces, restaurants, hospitals and more destroying the EPA’s 6 worst bacterial pathogens!——Earlier in 2005, I alerted my readers to the announcement that eFoodSafety Big Six Plus germicidal passed all tests for safely and completely eradicating the EPA’s six most dangerous bacterial pathogens:
1. e-coli
2. listeria
3. pseudomonoas
4. salmonella
5.
staphylococcus
6. streptococcus
——Big Six Plus is proven completely effective when used on hard and porous surfaces making it highly desirable for routine use in hospitals, kitchens, food storage areas, and many more locations where disease can be spread. I expect huge sales from this product line.
——Tests also prove that it’s 100% safe to spray and use around animals, food and humans, largely because the formula is comprised of nothing but food-safe components, previously approved by the FDA and EPA!
——This has created an incredible buying
opportunity for EFSF! Since the market has completely missed its latest announcement, you could make a fortune off eFoodSafety stock (EFSF) that you buy today.
——Last September, rumors of a breakthrough appear to have triggered a 24-hour, 214% share price explosion in EFSF stock. (9/12/05)...which are poised for tremendous share price growth as the company is moving toward fulfillment of its stated objectives.
Now that rumors have been verified, EFSF has become an urgent “Buy Now” opportunity!
——I would not wait to make your move.
I firmly believe that eFoodSafety could quickly skyrocket once this recently announced news reaches market ears.
——That’s not all…
——eFoodSafety has more products in the pipeline, some already generating revenue that could make the company hugely profitable as early as this year!
And most important, eFoodSafety is about to achieve positive cash flow!
——It's rare that an investor can find a ground-floor opportunity with explosive growth potential that has already established positive fundamentals.
——eFoodSafety hit this landmark early this year, which is why I'm urging investors to move quickly on its stock (EFSF). This buying opportunity can't last much longer!
——Here are a few of the products, in addition to Big Six Plus germicide, that are carrying eFoodSafety into the future...and could be featured in coming news releases:
Talsyn™ CI/bid Scar CreamThe most efficacious scar cream on the market today, entering a $4 billion market.
——Talsyn is effective in the treatment of new
and old scars and is particularly promising to the cosmetic surgery segment where 9.2 million procedures are performed annually.
——Talsyn also works to reduce old scars by an average of 62% over an 8-9 week treatment regimen. Available only through a physician, the product’s acceptance in surgery and clinics is soaring making it a potential huge money maker in 2006.
Cinnergen™ non-prescription diabetes productSales are already surpassing expectations on this important new product.
——Diabetes is becoming one of the fastest growing chronic health problems in America’s aging population.
It’s currently a $132 billion market.
——Cinnergen encapsulates a proven effective naturally occurring compound found in common cinnamon that can supplement subscription diabetes medications and help decrease medication needs in type 2 diabetic and borderline patients.
——Cinnergen can also forestall diabetes onset in at-risk patients. Distribution is already underway at Drugstore.com and Richard’s Whole Foods. Expect more in the works for major retail drug chains.
Trimmendous™ weight loss aidStaking a claim on a $33 billion market with a promising new weight-loss
therapy that is both compelling and unique.
——This product is an effedrine-free weight loss product that is specifically formulated for a two-dose regimen, one for morning use and one for pre-bedtime use.
——Trimmendous improves metabolism and lifts energy levels without using risky stimulants. This product enters a huge weight loss marketplace that, though crowded with claims, has unique selling and performance benefits that could readily capture a significant share of that market.
——As progress moves forward, I expect even greater gains with EFSF that I will forecast and follow for readers
of The KonLin Letter.
Step ahead of the investing crowd by following the picks and forecasts you receive in The KonLin Letter.
——If stocks like EFSF have a place in your portfolio (along with a carefully researched and analyzed selection of less speculative, growth-oriented stocks), I urge you to visit my website to learn how you can receive these recommendations on a monthly basis.
All risk-free of course!
Here's where you can get 5 more high-profit-potential stock picks like EFSF every month of the year…with a money-back
guarantee as well!
——The KonLin Letter is a recognized authority on finding and recommending low-priced stocks with great profit-making potential. It has become one of Wall Street’s leading investment newsletters and ranked among the best performing in the nation.
——Each month, subscribers receive 5 new low-priced stock selections, plus a featured stock of the month, reviews of 30-35 different stocks, plus technical indicators for market timing plays.
——If you want to learn more, here's where to find a recent sample of the
letter that subscribers receive!
——Visit The KonLin Letter website at: http://www.konlin.com
Yours for Profitable Investing 
Konrad Kuhn, Publisher
The KonLin Letter | Company: eFoodSafety.com, Inc.
Symbol: EFSF First Target: $2
Strategy: Buy and hold for sell signal from The KonLin Letter Recommendation:
Immediate BUY NOW! This is a high risk investment suitable only for aggressive investors. Please limit your investment to an amount you are comfortable putting at risk for loss. |
——P.S. Regular readers of The KonLin Letter know I do not make timing forecasts for buying
and selling my picks. When we see value, we recommend a buy. And when it comes time to sell, we pull the trigger and take our profits or losses.
——That’s why a subscription to The KonLin Letter can be a valuable tool for keeping your portfolio well in the black and well ahead of the investing masses.
——On the horizon:
——It obliterates Anthrax spores on hard and porous surfaces——eFoodSafety's anthrax sporicidal also meets all EPA protocol guidelines for a 100% kill of the surrogate
organisms used for the testing against anthrax. EPA registration is underway and should be approved yet this year. With this product, the bio-terror threat of weaponized anthrax could be completely neutered.
——Also...
——Watch for an announcement soon about an exciting new eFoodSafety skin care product that is reported to be better than the wildly popular “Proactiv™” line of products. If this pans out as I think it will, it could be a tremendous announcement for investors!
Disclaimer This profile published by OTC Live, Inc is an
independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of OTC Live, Inc and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. OTC Live, Inc is not a broker dealer or a registered investment advisor . It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While OTC Live, Inc believes its sources to be reliable, associates of OTC Live, Inc, or any affiliated parties make no representation
or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company. Factual statements in this publication are made as of the date stated and are subject to change without notice. OTC Live, Inc is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. OTC
Live, Inc has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any implication that there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. OTC Live, Inc of this advertisement has been compensated seven thousand dollars by a third party for the preparation and electronic dissemination of this report. This should be viewed as a potential conflict of interest. Furthermore, associates of OTC Live, Inc may have stock
positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes your acceptance of these terms and conditions. SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results.
These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,'' ``project,'' ``intend,'' ``plan,", "anticipate", "guess", "think", "hear", "suggest", ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small,
thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research." "Internet Fraud" is available on the SEC's Web Site, at http://www.sec.gov/consumer/cyberfr.htm.
